In the LIBERTY-PN PRIME and PRIME2 phase 3 trials, dupilumab, a monoclonal antibody that blocks IL-4 and IL-13 signaling, significantly reduced itch and skin lesions in patients with prurigo nodularis, a chronic inflammatory skin disease.
- Gil Yosipovitch
- Nicholas Mollanazar
- John T. O’Malley